DEFECTIVE TUMOR MITOCHONDRIA DRIVES INTRINSIC IMMUNOGENICITY THROUGH MHC CLASS 1 ANTIGEN PRESENTATION AND T-CELL ENGAGEMENT

Dana-Farber Cancer Institute, Inc.

Investigators